ABUS - Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
As of May 15, 2026: spot at $4.25, ATM IV 405.2%, net GEX -$14.0K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $848.8M
- P/E Ratio
- 5.20
- Beta
- 0.62
- 52-Week Range
- 2.94-5.1
- CEO
- Lindsay Androski
- Employees
- 44
- IPO Date
- Jul 26, 2007
- Exchange
- NASDAQ
What ABUS Looks Like to Options Traders Today
IV rank of 100.0% signals elevated pricing relative to the 1-year history, conditions that typically favor premium-selling structures (credit spreads, iron condors, covered calls); negative net gamma exposure (-$14.0K) means dealers hedge with trend, amplifying realized volatility and accelerating directional moves; the 25-delta skew (1.493) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The ABUS overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ABUS overview questions
- What is ABUS?
- ABUS is the ticker symbol for Arbutus Biopharma Corporation, a listed security. Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. Listed on NASDAQ. ABUS is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ABUS options snapshot look like today?
- As of May 15, 2026, the ABUS options snapshot shows spot at $4.25, ATM IV 405.2%, IV rank 100.0%, net GEX -$14.0K, expected move 116.17%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ABUS's key statistics?
- Arbutus Biopharma Corporation (ABUS) carries a market capitalization of $848.8M, trailing P/E ratio of 5.20, beta of 0.62 relative to the broader market, 52-week range of 2.94-5.1. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ABUS belong to?
- Arbutus Biopharma Corporation operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ABUS's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ABUS data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).